VIGMED GRANTED PATENT IN AUSTRALIA

The Australian Patent Office has now given Vigmed AB approval for an Australian Patent for IV Catheters (VIGMED CLiP®). The patent is Vigmed's first Australian Patent and is particularly important as the intellectual property that is protected can be applied to other products in development.

VIGMED CLiP is a unique self- activating and automatic needle protection for IV catheters which protects the patient as well as staff against accidental and potentially contaminated needle stick injury. The product, part of a whole family of products developed by Vigmed in response to the EU Directive on Sharps Safety, is extremely user friendly and safe, as well as being cost effective.

Vigmed works proactively with patent applications with the aim of protecting their unique products from being copied. With regard to VIGMED CLiP the company has previously been granted a US, a European, a separate Swedish Patent and a Chinese Utility Model.  Now the Australian Patent Office has informed Vigmed that they will grant an Australian Patent related to VIGMED CLiP.

Vigmed has so far submitted approximately 60 patent applications, divided into more than 10 patent families. Vigmed owns their patents and patent applications without restriction. The first patent application was submitted in late summer 2009. The foundation patents and patent applications all have priority dates from the period 2009 to 2014, which means they have almost maximum patent life.

The strategy is to protect Vigmed's technology and products in all geographical markets that are judged to be significant. Vigmed intends to increase their patent portfolio continuously with both offensive and defensive patents and Utility Models.

For further information contact:

Chairman of the board, Lennart Holm +46 70-630 8562 or CEO, Finn Ketler +46 42 600 5311

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 15 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately
5 400 shareholders. Remium Nordic AB is the Company’s Certified Advisor.

Additional information such as company description, a video presentation and risk factors can be found on Vigmed’s website: www.vigmed.com/investor

Tags: